This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Ultragenyx Pharmaceutical Inc.

Drug Names(s): rhPPCA, Recombinant human protective protein cathepsin-A

Description: UX004 is a recombinant human protective protein cathepsin-A, or rhPPCA, intended as an enzyme replacement therapy for galactosialidosis, a rare lysosomal storage disease.

Deal Structure: Ultragenyx and St. Jude Children's Research Hosptial
In September 2012, Ultragenyx in-licensed recombinant human protective protein cathepsin-A, or rhPPCA, from St. Jude Childrens Research Hospital.

UX004 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug